Shuaiying Cui, PhD
Associate Professor, Medicine
Biography
Dr. Cui’s research has focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through a series of epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation and demethylation. Such agents can be applied to the treatment of the patients with hematologic disorders such as sickle cell disease and beta-thalassemia, as well as acute myeloid leukemia (Blood cancer), which arise from congenital defects in genome. The findings from these preclinical studies could also help to establish therapeutic indications in other hematological malignancies.
Other Positions
- Member, Center for Excellence in Sickle Cell Disease, Boston University
Education
- University of Science and Technology of China, PhD
- Anhui University, BS
Publications
- Published on 7/31/2024
Sun Y, Benmhammed H, Al Abdullatif S, Habara A, Fu E, Brady J, Williams C, Ilinski A, Sharma A, Mahdaviani K, Alekseyev YO, Campbell JD, Steinberg MH, Cui S. PGC-1a agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease. Sci Adv. 2024 Aug 02; 10(31):eadn8750. PMID: 39083598.
Read at: PubMed - Published on 2/4/2022
Sun Y, Habara A, Le CQ, Nguyen N, Chen R, Murphy GJ, Chui DHK, Steinberg MH, Cui S. Pharmacologic induction of PGC-1a stimulates fetal haemoglobin gene expression. Br J Haematol. 2022 Apr; 197(1):97-109. PMID: 35118652.
Read at: PubMed - Published on 1/26/2022
Aygun B, Bello A, Thompson AA, Davis L, Sun Y, Luo HY, Cui S, Chui DHK. Clinical phenotypes of three children with sickle cell disease caused by HbS/Sicilian (dß)0 -thalassemia deletion. Am J Hematol. 2022 04; 97(4):E156-E158. PMID: 35045200.
Read at: PubMed - Published on 9/27/2021
Li X, Chen M, Liu B, Lu P, Lv X, Zhao X, Cui S, Xu P, Nakamura Y, Kurita R, Chen B, Huang DCS, Liu DP, Liu M, Zhao Q. Transcriptional silencing of fetal hemoglobin expression by NonO. Nucleic Acids Res. 2021 09 27; 49(17):9711-9723. PMID: 34379783.
Read at: PubMed - Published on 4/16/2019
Le CQ, Myers G, Habara A, Jearawiriyapaisarn N, Murphy GJ, Chui DHK, Steinberg MH, Engel JD, Cui S. Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis. Blood. 2019 05 30; 133(22):2455-2459. PMID: 30992270.
Read at: PubMed - Published on 1/31/2018
Tang B, Wang S, Wang SG, Wang HJ, Zhang JY, Cui SY. Invertebrate Trehalose-6-Phosphate Synthase Gene: Genetic Architecture, Biochemistry, Physiological Function, and Potential Applications. Front Physiol. 2018; 9:30. PMID: 29445344.
Read at: PubMed - Published on 11/29/2017
Morrison TA, Wilcox I, Luo HY, Farrell JJ, Kurita R, Nakamura Y, Murphy GJ, Cui S, Steinberg MH, Chui DHK. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis. 2018 03; 69:1-9. PMID: 29227829.
Read at: PubMed - Published on 9/1/2017
de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80. PMID: 28867658.
Read at: PubMed - Published on 2/24/2017
Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, Lavelle D, Rivers A. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp Hematol. 2017 06; 50:46-52. PMID: 28238805.
Read at: PubMed - Published on 1/1/2017
Cui S, Engel JD. Reactivation of Fetal Hemoglobin for Treating ß-Thalassemia and Sickle Cell Disease. Adv Exp Med Biol. 2017; 1013:177-202. PMID: 29127681.
Read at: PubMed
View 16 more publications: View full profile at BUMC